| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -1.5 | -3.4 |
| EPS (diluted, $ a share) | $-0.69 | $-35.88 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: GRI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
GRI Bio, Inc.: key numbers
- Share price
- $1.40Close, Nov 16
- Market cap
- $3.06M
- Shares outstanding
- 2.19MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from GRI Bio, Inc.
All →GRI Bio Shareholder Meeting
GRI Bio held its 2026 Annual Meeting of Stockholders where shareholders elected W. Marc Hertz and David Szekeres as Class III directors and ratified WithumSmith+Brown, PC as the independent auditor. Stockholders also approved an amendment to the 2018 Equity Incentive Plan, increasing the share reserve by 546,529 shares and extending the evergreen provision to 2036.